Tiazac (Diltiazem Hydrochloride) - Summary

TIAZAC SUMMARY

Tiazac® (diltiazem hydrochloride) is a calcium ion cellular influx inhibitor (slow channel blocker).

Tiazac® is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications.

Tiazac® is indicated for the treatment of chronic stable angina.

TIAZAC NEWS HIGHLIGHTS

Published Studies Related to Tiazac (Diltiazem)

Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study. [2008.07]

Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation. [2007.03]

Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]

Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. [2006.05]

Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. [2005.10]

more>>

Clinical Trials Related to Tiazac (Diltiazem)

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg [Completed]

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg [Completed]

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]

more>>